Home › Multiple Myeloma › Louisiana
Multiple Myeloma clinical trials in Louisiana
9 studies for Multiple Myeloma are looking for participants at sites in Louisiana.
Cities in Louisiana
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0385, Shreveport
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05519085A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- LSU Health Feist Weiller Cancer Center, Shreveport
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Mary Bird Perkins Cancer Center, Baton Rouge
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07609940A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- LSUHSC Shreveport Feist-Weiller Cancer Center, Shreveport
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Pontchartrain Cancer Center, Covington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07477587A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Louisiana State University Health Sciences Shreveport, Shreveport
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06615479A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Baton Rouge
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baton Rouge
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tulane University School of Medicine /ID# 251204, New Orleans
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.